10x Genomics director sells 20,000 shares

Director John R. Stuelpnagel reported open-market sales totaling 20,000 TXG shares on September 3, 2026 across three weighted-average price ranges.

Rhea-AI Filing Summary

10x Genomics, Inc. (TXG) director John R. Stuelpnagel reported selling a total of 20,000 shares of Class A common stock on September 3, 2026 in open-market transactions. The shares were sold in three blocks at weighted average prices around $60.66, $62.11, and $62.61, each executed across multiple trade prices, and no Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Net Seller: 20,000 shares

Net Sell 3 txns

Insider STUELPNAGEL JOHN R

Role Director

Sold 20,000 shs ($1.24M)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock F1	7,012	$60.6579	$425K
Sale	Class A Common Stock F2	6,814	$62.1082	$423K
Sale	Class A Common Stock F3	6,174	$62.6066	$387K

Holdings After Transaction: Class A Common Stock — 328,436 shares (Direct)

Footnotes (3)

1. F1. This transaction was executed in multiple trades at prices ranging from $60.435 to $61.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
2. F2. This transaction was executed in multiple trades at prices ranging from $61.435 to $62.35. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
3. F3. This transaction was executed in multiple trades at prices ranging from $62.50 to $62.86. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Key Figures

Total shares sold: 20,000 shares First sale block: 7,012 shares at $60.6579 per share Second sale block: 6,814 shares at $62.1082 per share +3 more

6 metrics

Total shares sold 20,000 shares Aggregate sales by director John R. Stuelpnagel on September 3, 2026

First sale block 7,012 shares at $60.6579 per share Class A common stock sale on September 3, 2026; trades ranged from $60.435 to $61.01

Second sale block 6,814 shares at $62.1082 per share Class A common stock sale on September 3, 2026; trades ranged from $61.435 to $62.35

Third sale block 6,174 shares at $62.6066 per share Class A common stock sale on September 3, 2026; trades ranged from $62.50 to $62.86

Reported transaction count 3 sale entries Non-derivative open-market or private sales of Class A common stock

Derivative positions reported 0 No remaining derivative securities listed in this Form 4

Key Terms

weighted average sale price, multiple trades, open market or private transaction

3 terms

weighted average sale price financial

"The price reported above reflects the weighted average sale price."

multiple trades financial

"This transaction was executed in multiple trades at prices ranging from..."

open market or private transaction financial

"described as a sale in open market or private transaction"

FAQ

What insider transaction did TXG director John R. Stuelpnagel report?

He reported selling 20,000 shares of 10x Genomics Class A common stock on September 3, 2026 in open-market transactions, split across three separate sale entries at different weighted average prices.

How many TXG shares did John R. Stuelpnagel sell and on what date?

John R. Stuelpnagel sold a total of 20,000 shares of 10x Genomics Class A common stock on September 3, 2026, reported as three separate blocks of 7,012 shares, 6,814 shares, and 6,174 shares.

At what prices were John R. Stuelpnagel’s TXG share sales executed?

The filing reports weighted average sale prices of $60.6579, $62.1082, and $62.6066 per share. Footnotes state the underlying trades ranged from $60.435–$61.01, $61.435–$62.35, and $62.50–$62.86, respectively.

Were John R. Stuelpnagel’s TXG sales made under a Rule 10b5-1 trading plan?

The filing indicates that no Rule 10b5-1 trading plan was reported in connection with these transactions, meaning the sales are not identified as being executed under a pre-arranged trading plan.

Did the Form 4 report any option exercises or derivative transactions for TXG?

No. The Form 4 reports only open-market sales of common stock totaling 20,000 shares and shows no derivative transactions or option exercises in the reported period.

Does the Form 4 show John R. Stuelpnagel’s remaining TXG share holdings after the sales?

The reported sale entries list the shares sold but do not provide a share balance after the transactions. The post-transaction holding fields for these entries are left blank in the filing data.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/08/2026 - 07:00 PM Accepted by SEC EDGAR 09/08/2026 - 07:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

STUELPNAGEL JOHN R

(Last) (First) (Middle)

C/O 10X GENOMICS, INC.

6230 STONERIDGE MALL ROAD

(Street)

PLEASANTON CALIFORNIA 94588

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
10x Genomics, Inc. [ TXG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	09/03/2026		S		7,012	D	$60.6579(1)	341,424	D
Class A Common Stock	09/03/2026		S		6,814	D	$62.1082(2)	334,610	D
Class A Common Stock	09/03/2026		S		6,174	D	$62.6066(3)	328,436	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed in multiple trades at prices ranging from $60.435 to $61.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

2. This transaction was executed in multiple trades at prices ranging from $61.435 to $62.35. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

3. This transaction was executed in multiple trades at prices ranging from $62.50 to $62.86. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

	/s/ Randy Wu, as Attorney-in-Fact for John R. Stuelpnagel	09/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)